Podcasts about t2 biosystems

https://youtu.be/W5PeGIMUbpATry VectorVest for only $0.99  ➥➥➥ https://www.vectorvest.com/YTVectorVest Merch Store  ➥➥➥ https://vectorvest.com/MerchandiseWelcome to our YouTube video on T2 Biosystems! In this informative session, we will delve into whether T2 Biosystems is simply a meme or a legitimate hot penny stock. T2 Biosystems, a cutting-edge biotechnology company, is making waves in the stock market, and we're here to uncover the truth behind the hype. Join us as we analyze the key factors that contribute to its potential as an investment opportunity. Firstly, we will explore T2 Biosystems' revolutionary products and technologies. The company specializes in developing diagnostic solutions using its proprietary T2 Magnetic Resonance (T2MR) technology. T2MR enables rapid and accurate detection of pathogens, making it a game-changer in diagnosing life-threatening infections. We will discuss the significance of this technology and its potential impact on the medical industry. Next, we'll evaluate T2 Biosystems' financial performance and growth prospects. By examining the company's revenue trends, market positioning, and competitive advantage, we aim to assess its long-term profitability. Additionally, we will analyze the potential risks associated with investing in hot penny stocks like T2 Biosystems, ensuring you have a well-rounded understanding of the opportunity. Furthermore, we'll examine the recent buzz surrounding T2 Biosystems. With a surge in attention from investors and social media discussions, it's crucial to separate the hype from the substance. We will present an unbiased analysis of the factors contributing to T2 Biosystems' popularity and ensure you have a comprehensive view of its current status. Lastly, we'll conclude by offering our insights and expert opinion on whether T2 Biosystems is a meme-induced frenzy or a genuinely hot penny stock with substantial growth potential. Whether you're a seasoned investor or someone exploring lucrative investment avenues, this video will provide you with valuable insights into T2 Biosystems' investment prospects. Stick around until the end as we provide links to additional resources and references for further research. Don't miss out on this opportunity to uncover the truth behind T2 Biosystems and gain a deeper understanding of its investment worthiness! Remember to like, share, and subscribe to our channel for more intriguing investment analyses and discussions. Stay informed and make wise investment decisions with us. Let's dive into the T2 Biosystems craze and separate the meme from the genuine hot penny stock!T2 Biosystems: Unveiling the Hype! Meme or Genuine Hot Penny Stock? (TTOO Stock) | VectorVestUse this link for a FREE Stock Analysis Report ➥➥➥ vectorvest.com/YTFSASUBSCRIBE To The VectorVest Channel ➥➥➥ https://www.youtube.com/user/VectorVestMB/?sub_confirmation=1

World class psychic Kapproveb timing highs and lows to the hour using Eso-Meta analysis. ABOUT OUR CHANNEL Our channel is about Live Tarot S&P 500 Predictions. We cover topics such as Tarot Market Predictions, Stocks, ESO - Meta Analysis and much more. Don't forget to subscribe! We sell these awesome products, check them out here: https://www.tarotfortraders.com/private-sessions https://www.tarotfortraders.com/eso-meta-forecasts https://www.tarotfortraders.com/shop FIND US AT https://www.tarotfortraders.com/ FOLLOW US ON SOCIAL Get updates or reach out to Get updates on our Social Media Profiles! Twitter: https://twitter.com/tarotfortradersFacebook: https://www.facebook.com/TarotforTraders/Instagram: https://www.instagram.com/tarotfortraders/TikTok: https://www.tiktok.com/@tarot4tradersBlog: https://www.tarotfortraders.com/forecasts Disclaimer: This content and all content by TarotForTraders.com is for informational purposes only, you should not misconstrue any such information or other material as legal, tax, investment, financial, or other advice.

World class psychic Kapproveb timing highs and lows to the hour using Eso-Meta analysis. ABOUT OUR CHANNEL Our channel is about Live Tarot S&P 500 Predictions. We cover topics such as Tarot Market Predictions, Stocks, ESO - Meta Analysis and much more. Don't forget to subscribe! We sell these awesome products, check them out here: https://www.tarotfortraders.com/private-sessions https://www.tarotfortraders.com/eso-meta-forecasts https://www.tarotfortraders.com/shop FIND US AT https://www.tarotfortraders.com/ FOLLOW US ON SOCIAL Get updates or reach out to Get updates on our Social Media Profiles! Twitter: https://twitter.com/tarotfortradersFacebook: https://www.facebook.com/TarotforTraders/Instagram: https://www.instagram.com/tarotfortraders/TikTok: https://www.tiktok.com/@tarot4tradersBlog: https://www.tarotfortraders.com/forecasts Disclaimer: This content and all content by TarotForTraders.com is for informational purposes only, you should not misconstrue any such information or other material as legal, tax, investment, financial, or other advice.

Pablo is a technical expert with a focus on medical devices and checkpoint security industries, he has a pHD in physics from University of New Brunswick and was the product introduction lead for 6 products currently in the market from concept to commercialization. He is the Founder & CEO of ORS and One Resonance, the President of Turbospec, and has been the VP of Engineering at Quasar Federal Systems, CTO at Progression Inc., VP of Development at T2 Biosystems (trading TTOO), and Senior Manager and Product Introduction Lead at GE and Quantum Magnetics. He is also the author of 10 patents, 2 book chapters, and more than 40 scientific articles. On this episode he covers why fatty liver is called the silent disease, his method for point of care diagnosis at Livivos by introducing accuracy of MRI but at the price and ease of use of ultrasound, the overlooked concept of preventive medicine for liver health, regions of the world where the disease is more prominent, the key skills and knowledge he looks for when hiring, how he came up with the idea for his company and the reality of running a small business together with the sacrifices he had to make. Get in touch with Pablo J Prado - https://www.linkedin.com/in/pablojprado/or visit his company website - http://livivos.com/ Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/c/QRAMedical Subscribe to the Podcast

This week, Stacey is joined by Robin Toft to talk about the challenges of attracting and hiring top talent, tactics for building and retaining a workforce, and the technologies that are changing the ways we recruit, hire, and train our teams. Stacey and Robin also discuss which areas are in the most demand, talent management strategies, career path planning, and much more. Resources from this episode: Talent 2020: Surveying The Talent Paradox From The Employee Perspective: The View From The Life Sciences Sector https://www2.deloitte.com/content/dam/Deloitte/mx/Documents/human-capital/Talent_2020_LifeSciences.pdf WE CAN: The Executive Woman's Guide to Career – on Amazon https://www.amazon.com/WE-CAN-Executive-Womans-Advancement/dp/1949635031 WE CAN: The Executive Woman's Guide to Career – on Goodreads https://www.goodreads.com/book/show/43533323-we-can We Can Rise Community https://wecanrisecommunity.com/ About Our Guest: Robin Toft is the founder and CEO of Toft Group a ZRG Company, where she combines a deep inside knowledge of the life science industry with a passion for building game-changing management teams. A champion of diverse executive teams, Robin has built a reputation for recruiting women and minorities into top roles and helping the life science industry overcome unconscious bias in hiring. Having successfully sold Toft Group to ZRG Partners, Robin co-founded We Can Rise in 2020, a B-corporation aimed at helping aspiring female executives to confidently reach their potential while achieving balance and collaborating to build healthier companies that change the world. Prior to founding Toft Group in 2010, Robin served 20+ years as a biotech executive. Robin's first book entitled WE CAN, The Executive Woman's Guide to Career Advancement, is recognized within the list of 100 Best CEO Books of All Time by BookAuthority and won Gold for Best E-book in the International Business Awards. In the American Business Awards for 2020, Robin won Gold in the three major individual categories of Lifetime Achievement, Maverick of the Year, and Woman of the Year. She also won Gold for Most Innovative Woman of the Year in the Women in Business Awards for 2020. Robin currently serves on the boards of T2 Biosystems, Syapse, California Life Science Association (CLSA), The Clearity Foundation, and LEAD San Diego. Robin holds a B.S. in Medical Technology from Michigan State. Voices in Validation brings you the best in validation and compliance topics. Voices in Validation is brought to you by IVT Network, your expert source for life science regulatory knowledge. For more information on IVT Network, check out their website at http://ivtnetwork.com. 

❤️ Loved it!👎 Meh…Summary transcript: https://www.listory.com/ll/7f2e4a3c198bdbf1ac436c8cad51c94ba34f379bOriginal story: https://finance.yahoo.com/news/billionaire-israel-englander-bets-2-143857211.htmlDescription: Let's talk about risk, reward, and pennies. The three are related, of course. There's no reward in the stock market without taking on some risk – and penny stocks offer investors an optimum combination of both. The ‘pennies' are the lowest cost stocks on the public markets, typically priced below $5 per share. At such a low share price, even a small gain – a share price increase of mere pennies – can quickly translate into a high-percentage return. However, there is a but here. The critics point out that there could be a reason for the bargain price tag, whether it be poor fundamentals or overpowering headwinds. So, how are investors supposed to determine which penny stocks are poised to make it big? Following the activity of the investing titans is one strategy. Enter Israel “Izzy” Englander, who is widely known for his impressive stock picking abilities. Englander expressed interest in the stock market since he was young, and in 1989, co-founded hedge fund Millennium Management with Ronald Shear. Using a broad range of strategies involving a variety of predominantly liquid asset classes, Englander was able to take the $35 million the fund was started with and turn it into a $45+ billion Wall Street behemoth. With an estimated net worth of $9.6 billion in 2021, it's no wonder Wall Street focus locks in on the guru when he makes a move. Taking all of this into consideration, we used TipRanks' database to take a closer look at two penny stocks Englander snapped up recently. The platform revealed that both Buy-rated tickers have earned the support of some members of the analyst community as well. T2 Biosystems (TTOO) We'll start in the healthcare industry, where T2 Biosystems is working to revolutionize diagnostics. The company offers diagnosticians and medical labs a range of devices based on its T2 Magnetic Resonance (T2MR) tech to quickly and accurately diagnosis a variety of septic illnesses. As the company notes, sepsis claims more lives annually than AIDS, breast cancer, and prostate cancer combined. Rapid and accurate diagnosis is the key for patient survival, and this is the niche that T2 aims to fill. The company's technology enables diagnostic blood tests with results available in a matter of hours, compared to the 1 to 5 days currently taken by most medical lab tests. Available testing products include the T2Bacteria Panel and the T2Candida panel, which are the only FDA-approved blood tests for septic agents that do not need to wait for a blood culture. A T2SARS-CoV-2 Panel is also available, using upper respiratory samples. T2 has an active product pipeline, with rapid diagnostic tests on the drawing board for a variety of illnesses. Upcoming products include the T2Cauris panel and the T2Resistance panel. These testing products are currently designated for research use only (ROU) in the US. The T2Lyme panel, which will allow for faster diagnosis of the difficult-to-determine Lyme disease, is at an earlier stage of the development. All of T2's products operate on the same T2Dx instrument, allowing for interchangeability in the lab environment. The device offers a simple user interface, and operates with just 4ml of whole blood. T2 boasts that its device is in use in more than 200 hospitals worldwide. In the first quarter of 2021, T2 saw top-line revenue grow by 173% year-over-year, to $7 million. This was driven by a 345% yoy increase in product revenue, to $4.7 million. Sepsis test utilization in the US rose by 85% yoy in the quarter, showing increasing acceptance of the device and technology. Izzy Englander is among those that have high hopes for this healthcare name. In Q1, Englander's Millennium picked up over 1.36 million shares of TTOO stock, now valued at $1.5 million. This increased Englander's stake in the company to 2.68 million shares, with a market value of $2.9 million. 5-star analyst Charles Duncan, of Canaccord, also counts himself as a fan. Duncan gives TTOO shares a Buy rating along with a $3.50 price target. This target conveys his confidence in TTOO's ability to soar 212% higher in the next twelve months. (To watch Duncan's track record, click here) “T2's +345% Y/Y product revenue growth is a positive datapoint for the company's post-pandemic commercial strategy, which is being supported by a scaling to just under 10 direct sales reps in Q1. We view the acquisitions of Cepheid, BioFire, GenMark, and Luminex as validation that the hospital lab is an attractive industry segment, given clinicians' (and patients') desire to shift away from centralized testing strategies to a more decentralized approach. With these four companies off the table, T2 should benefit from scarcity value. Separately, a more aggressive approach towards commercial execution should marry well with rising awareness around antimicrobial resistance and sepsis, in a post-pandemic environment that prioritizes infectious disease diagnostics," Duncan noted. It turns out that other analysts also have high hopes. With 4 Buys and a single Hold, the word on the Street is that this stock, which currently going for $1.10 apiece, is a Strong Buy. In addition, the $2.83 average price target puts the upside potential at 156%. (See TTOO stock analysis on TipRanks) Sesen Bio (SESN) The second stock we're looking at, Sesen Bio, is a pharmaceutical company. Sesen works in the cancer treatment segment, developing antibody-drug conjugate therapies. The program takes a fusion protein approach, tethering tumor-targeting antibodies to cytotoxic proteins. The result is a single protein molecule that kills cancer cells with minimal toxic effects on the body – and that generates a complementary response from the patient's natural immune system. Sesen's pipeline currently includes one drug candidate, vicineum, which is under investigation on several tracks concurrently. The main track, which has completed clinical trials and initiated the submission process of the biologic license application (BLA), is for the treatment of non-muscle invasive bladder cancer. The BLA was accepted for filing by the FDA this past February, and the company is on track for potential approval on August 18, 2021. European approval of vicineum for bladder cancer treatment is expected early in 2022. The company's other pipeline projects are at earlier stages. Vicineum is under investigation as a treatment for head and neck cancers, and is in Phase 2 trials. Other investigative tracks remain at pre-clinical stages. Clinical-stage biopharma companies are always highly speculative, and in this case, Englander did not mind speculating. In Q1, his firm bought 987,926 shares of SESN, increasing its stake in the company by 156%. Englander's holding in Sesen is now valued at $2.9 million. Weighing in on SESN for H.C. Wainwright, 5-star analyst Swayampakula Ramakanth sees an opportunity as well. "Given the favorable risk/benefit profile of Vicineum demonstrated in the Phase 3 VISTA study, we believe the drug has a high likelihood to receive regulatory approvals from the FDA and EMA. Sesen is actively preparing for the potential launch of Vicineum. The company has selected Syneos, a leading contract sales organization, as a partnerto build and manage a 35-people sales force to target approximately 2,000 high prescribers of BCG. We expect the drug to be commercially available immediately upon approval. We project Vicineum to achieve risk-adjusted sales of $516M by 2030E, growing from $9M in 2021E," Ramakanth opined. Ramakanth's comments support his Buy rating on the stock, as does his $8 price target. At current valuations, that target implies an upside potential of 170% for the next 12 months. (To watch Ramakanth's track record, click here) Sometimes, the penny stocks can slide under the radar; this one has attracted only two recent analyst reviews. Both agree, however, that this is a stock to buy, making the Moderate Buy consensus unanimous. The shares are priced at $2.94 with a $7.50 average price target that suggests an upside of 155% in the coming year. (See SESN stock analysis on TipRanks) To find good ideas for penny stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a newly launched tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Russ and Sully talk with Larry Reaugh about how Lithium-ion and manganese will affect all of our daily lives very soon. Then, John Sperzel talks about what T2 Biosystems is and what that means in the business of health. Plus, how Novo Integrated is building the next generation of healthcare companies.

John Sperzel, CEO of T2 Biosystems, stops by Let's Talk Medtech to chat about his newly published book, "Courage: Powerful Lessons in Leadership, Strength, and the Will to Succeed."

On this week’s Tech Nation, Fast Company columnist Jonah Sachs. His book is “Unsafe Thinking: How to Be Nimble and Bold When You Need It Most”. Then on Tech Nation Health, Dr. Tom Lowery from T2 Biosystems – their part in fighting life-threatening Sepsis. And David Domzalski from Foamix Pharmaceuticals talks about a new approach to America’s most common skin disorder: Acne.

On this week’s Tech Nation, Fast Company columnist Jonah Sachs. His book is “Unsafe Thinking: How to Be Nimble and Bold When You Need It Most”. Then on Tech Nation Health, Dr. Tom Lowery from T2 Biosystems – their part in fighting life-threatening Sepsis. And David Domzalski from Foamix Pharmaceuticals talks about a new approach to America’s most common skin disorder: Acne.

On this week’s Tech Nation, Fast Company columnist Jonah Sachs. His book is “Unsafe Thinking: How to Be Nimble and Bold When You Need It Most”. Then on Tech Nation Health, Dr. Tom Lowery (“L’ow!-ree”) from T2 Biosystems – their part in fighting life-threatening Sepsis. And David Domzalski from Foamix Pharmaceuticals talks about a new approach to America’s most common skin disorder: Acne.

On this week’s Tech Nation Health, Dr. Tom Lowery (“L’ow!-ree”) from T2 Biosystems – their part in fighting life-threatening Sepsis. And David Domzalski from Foamix Pharmaceuticals talks about a new approach to America’s most common skin disorder: Acne.

On this week’s Tech Nation, Fast Company columnist Jonah Sachs. His book is “Unsafe Thinking: How to Be Nimble and Bold When You Need It Most”. Then on Tech Nation Health, Dr. Tom Lowery (“L’ow!-ree”) from T2 Biosystems – their part in fighting life-threatening Sepsis. And David Domzalski from Foamix Pharmaceuticals talks about a new approach to America’s most common skin disorder: Acne.

On this week's Tech Nation, former Google CEO and Alphabet Executive Chair, Eric Schmidt along with former Senior Vice President for Products, Jonathan Rosenberg talk about “How Google Works”. Then on Tech Nation Health, faster diagnostics for the 25 species of bacteria which cause Sepsis. John McDonough, the CEO of T2 Biosystems, talks about their efforts in Sepsis and other new diagnostics for candida and Lyme disease.

On this week’s BioTech Nation, former Google CEO and Alphabet Executive Chair, Eric Schmidt along with former Senior Vice President for Products, Jonathan Rosenberg talk about “How Google Works”. Then on Tech Nation Health, faster diagnostics for the 25 species of bacteria which cause Sepsis. John McDonough, the CEO of T2 Biosystems, talks about their efforts in Sepsis and other new diagnostics for candida and Lyme disease.

On Tech Nation Health, faster diagnostics for the 25 species of bacteria which cause Sepsis. John McDonough, the CEO of T2 Biosystems, talks about their efforts in Sepsis and other new diagnostics for candida and Lyme disease.